Specialty Chemical Stock Under Rs 50 Plans Fundraise, Expands International Footprint With Dubai Acquisition

Sudarshan Pharma Industries Limited (SPIL) said its board will gather on Thursday, June 19, 2025, to review a fresh fundraising plan and, if all goes well, give it the green light. A notice sent to regulators spells out that the fund-raising move could involve new equity shares or other shares-like instruments such as convertible notes or warrants, though every legal approval will still be needed.

The planned cash injection shows SPIL wants to beef up its balance sheet so it can chase growth projects at home and push harder overseas.

In a fresh boost for SPIL, the Directorate General of Foreign Trade (DGFT) awarded the outfit its One Star Export House badge. Effective from May 8, 2025, and lasting until March 31, 2028, the accolade signals SPIL's growing clout in global sales.

To lock in that momentum, SPIL is buying Dubai-based Cibachem General Trading L.L.C. for Rs 55 lakh, or 300 shares. Approval from the Reserve Bank of India is still pending, though completion is expected by September 30, 2025. The acquisition aims to broaden SPIL's Middle East customer base, boost export receipts, and leverage Cibachem's country-wide trading web.

Founded in 2013, Cibachem has delivered steady income: AED 499,250 in 2024, AED 351,050 in 2023, and AED 492,588 in 2022.

Closer to home, SPIL's financials remain strong. For the second half of FY25, net sales jumped 19% to Rs 277 crore and net profit surged 43% to Rs 7 crore, compared with a year earlier. On an annual basis, FY25 sales climbed 9% to Rs 505 crore and profit soared 45% to Rs 16 crore.

The company credits this gain mainly to its new strategy of reselling active pharmaceutical ingredients in India, a shift that sharply boosted EBITDA margins and profit after tax in H2 FY25.

SPIL now sits with a market value of Rs 731 crore and has posted a healthy 37 per cent compound annual growth rate in profit over the past five years.

Founded in 2008 and based in Mumbai, SPIL is a well-respected contract maker of generic medicines. The company also makes speciality chemicals, active pharmaceutical ingredients, intermediates and finished generics for customers both in India and abroad.

Under its Vimac Healthcare name, SPIL has begun marketing its own branded drugs. Of the 96 formulations in its lineup, 56 carry the registered R label, boosting name awareness and protecting the company's intellectual property.

The company teams up with leading Indian drug-makers and research centres, delivers complete contract-manufacturing solutions, and backs its work with a long-standing reputation for quality, compliance, and customer care.

Aiming for fresh markets, pushing overseas, and sitting on a strong balance sheet, SPIL keeps stepping forward as an energetic player in India's fast-expanding pharma field.